Kimberly-Clark agreed to acquire Kenvue in a cash-and-stock deal valuing the Johnson & Johnson spin-off at about $48.7 billion in enterprise value. Kenvue holders are set to receive $3.50 in cash plus 0.14625 Kimberly-Clark shares per Kenvue share, equal to $21.01 per share based on October 31 pricing, a 46% premium to Kenvue’s prior close.…
Texas sues Kenvue claiming it hid link between Tylenol and autism
Ken Paxton, the Republican attorney general of Texas, sued Kenvue, the manufacturer of Tylenol, on Tuesday, for “deceptively marketing Tylenol to pregnant mothers despite knowing that early exposure to acetaminophen leads to a significantly increased risk of autism and other disorders,” according to the press release. J&J illegally offloaded liability, Paxton claims Paxton also claimed…
Kenvue pushes back on possible Tylenol label change
Following a White House press conference on Sept. 22, during which Donald Trump alleged a link between acetaminophen use during pregnancy and autism, the Informed Consent Network (ICAN) filed a petition with the FDA to add a warning to all drugs that contain acetaminophen. ICAN is a nonprofit organization that aims to provide “every person…
Johnson & Johnson pharma rebrand highlights innovation as a pillar to reinforce trust
Global pharma and medical device giant Johnson & Johnson (J&J) has ditched its iconic cursive logo that dates back to the late 19th century, and rebranded its Janssen pharma division as Johnson & Johnson Innovative Medicine. The move underscores the company’s push to prioritize higher-margin prescription drugs. This strategic move comes amidst a backdrop of…